NCT02318303 - To Study GSP 301 in Patients With Seasonal Allergic Rhinitis | Biotech Hunter

Enrollment

1,111

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

Seasonal Allergic Rhinitis

Interventions

DRUG

GSP 301-1 NS (QD)

GSP 301-1 NS (665 μg olopatadine hydrochloride/50 μg mometasone furoate) administered as 2 sprays/nostril

DRUG

GSP 301-2 NS (BID)

GSP 301-2 NS (665 μg olopatadine hydrochloride/25 μg mometasone furoate) administered as 2 sprays/nostril

DRUG

GSP 301 Placebo NS

GSP 301 placebo NS administered as 2 sprays/nostril

DRUG

Olopatadine HCl-1 NS (QD)

Olopatadine HCl-1 NS (665 μg) administered as 2 sprays/nostril

DRUG

Olopatadine HCl-2 NS (BID)

Olopatadine HCl-2 NS (665 μg) administered as 2 sprays/nostril

DRUG

Mometasone Furoate-1 NS (QD)

Mometasone furoate -1 NS (50 μg) administered as 2 sprays/nostril

DRUG

Mometasone Furoate-2 NS (BID)

Mometasone furoate-2 NS (25 μg) administered as 2 sprays/nostril

Trial Locations (10)

Glenmark Investigational Site 10, Austin

Glenmark Investigational Site 5, Austin

Glenmark Investigational Site 6, Austin

Glenmark Investigational Site 2, Kerrville

Glenmark Investigational Site 7, New Braunfels

Glenmark Investigational Site 3, San Antonio

Glenmark Investigational Site 4, San Antonio

Glenmark Investigational Site 8, San Antonio

Glenmark Investigational Site 9, San Antonio

Glenmark Investigational Site 1, Waco